Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Notification of Major Interest in Shares

16th Jun 2011 17:59

RNS Number : 6094I
Alliance Pharma PLC
16 June 2011
 



For immediate release

16 June 2011

 

Alliance Pharma plc

 

TR-1: Notification of major interest in shares

 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached:

Alliance Pharmaplc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in theacquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

On market transfer between direct and indirect funds

3. Full name of person(s) subject to thenotification obligation:

Aviva plc & its subsidiaries

4. Full name of shareholder(s) (if differentfrom 3.):

Registered Holder:

 

BNY Norwich Union Nominees Limited 3,484,351*  

Chase (GA Group) Nominees Limited 20,832,404*

 

*denotes direct interest

 

5. Date of the transaction and date onwhich the threshold is crossed orreached:

15 June 2011

6. Date on which issuer notified:

16 June 2011

7. Threshold(s) that is/are crossed orreached:

9% to 10% Change at Direct Interest Level

 

8. Notified details:

A: Voting rights attached to shares

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights

Direct

Direct

Indirect

Direct

Indirect

Ordinary SharesGB0031030819

Direct:

23,814,269

Indirect:

502,486

Direct:

23,814,269

Indirect:

502,486

24,316,755

24,316,755

Nil Held

10.16%

Nil Held

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate

Exercise/Conversion Period

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date

Exercise/Conversion period

Number of voting rights instrument refers to

 

% of voting rights

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

24,316,755

10.16%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

The voting rights are managed and controlled byAviva Investors Global Services Limited, with the following chain of controlled undertakings:-

 

Aviva Investors Global Services Limited:

·; Aviva plc (Parent Company)

·; Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

·; Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

·; Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)

 

Proxy Voting:

10. Name of the proxy holder:

See Section 4

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

Figures are based on a revised total number of voting rights of 239,394,534 per the company's Exercise of Share Options Announcement of 10 June 2011.

14. Contact name:

Neil Whittaker, Aviva plc

15. Contact telephone number:

01603 684420

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEAKKKFSXFEFF

Related Shares:

Alliance PharmaAviva
FTSE 100 Latest
Value8,809.74
Change53.53